O	0	11	Feasibility
O	12	15	and
O	16	22	Health
O	23	31	Benefits
O	32	34	of
O	35	37	an
B-intervention	38	52	Individualized
I-intervention	53	61	Physical
I-intervention	62	70	Activity
O	71	83	Intervention
O	84	86	in
B-eligibility	87	92	Women
I-eligibility	93	97	With
I-eligibility	98	108	Metastatic
I-eligibility	109	115	Breast
I-eligibility	116	122	Cancer
O	122	123	:
O	124	136	Intervention
O	137	142	Study
O	142	143	.

O	144	149	There
O	150	152	is
O	153	160	limited
O	161	170	knowledge
O	171	180	regarding
O	181	184	the
O	185	194	potential
O	195	203	benefits
O	204	206	of
O	207	215	physical
O	216	224	activity
O	225	227	in
O	228	236	patients
O	237	241	with
O	242	252	metastatic
O	253	259	breast
O	260	266	cancer
O	266	267	.

O	268	271	The
O	272	280	Advanced
O	281	286	stage
O	287	293	Breast
O	294	300	cancer
O	301	304	and
O	305	314	Lifestyle
O	315	323	Exercise
O	324	325	(
O	325	329	ABLE
O	329	330	)
O	331	336	Trial
O	337	342	aimed
O	343	345	to
O	346	352	assess
O	353	356	the
O	357	368	feasibility
O	369	371	of
O	372	373	a
O	374	382	physical
O	383	391	activity
O	392	404	intervention
O	405	407	in
O	408	413	women
O	414	418	with
O	419	429	metastatic
O	430	436	breast
O	437	443	cancer
O	444	447	and
O	448	450	to
O	451	458	explore
O	459	462	the
O	463	470	effects
O	471	473	of
O	474	482	physical
O	483	491	activity
O	492	494	on
O	495	505	functional
O	505	506	,
O	507	520	psychological
O	520	521	,
O	522	525	and
O	526	534	clinical
O	535	545	parameters
O	545	546	.

O	547	550	The
O	551	555	ABLE
O	556	561	Trial
O	562	565	was
O	566	567	a
O	568	574	single
O	574	575	-
O	575	578	arm
O	578	579	,
B-control	580	581	6
I-control	581	582	-
I-control	582	587	month
O	588	600	intervention
O	601	606	study
O	607	611	with
O	612	613	a
O	614	618	home
O	618	619	-
O	619	624	based
O	624	625	,
O	626	638	unsupervised
O	638	639	,
O	640	643	and
O	644	656	personalized
O	657	664	walking
O	665	672	program
O	673	678	using
O	679	681	an
O	682	690	activity
O	691	698	tracker
O	698	699	.

O	700	702	At
O	703	711	baseline
O	712	715	and
O	716	717	6
O	718	724	months
O	724	725	,
O	726	728	we
O	729	737	assessed
O	738	753	anthropometrics
O	753	754	,
O	755	765	functional
O	766	773	fitness
O	773	774	,
O	775	783	physical
O	784	792	activity
O	793	798	level
O	798	799	,
O	800	809	sedentary
O	810	818	behavior
O	818	819	,
O	820	827	quality
O	828	830	of
O	831	835	life
O	835	836	,
O	837	844	fatigue
O	844	845	,
O	846	849	and
O	850	855	tumor
O	856	867	progression
O	867	868	.

O	869	875	Paired
O	876	887	proportions
O	888	892	were
O	893	901	compared
O	902	907	using
O	908	911	the
O	912	919	McNemar
O	920	924	test
O	925	928	and
O	929	936	changes
O	937	939	of
O	940	950	parameters
O	951	957	during
O	958	961	the
O	962	974	intervention
O	975	979	were
O	980	988	analyzed
O	989	994	using
O	995	998	the
O	999	1007	Wilcoxon
O	1008	1014	signed
O	1014	1015	-
O	1015	1019	rank
O	1020	1024	test
O	1024	1025	,
O	1026	1029	the
O	1030	1034	Mann
O	1034	1035	-
O	1035	1042	Whitney
O	1043	1047	test
O	1047	1048	,
O	1049	1052	and
O	1053	1061	Spearman
O	1062	1066	rank
O	1067	1079	correlations
O	1079	1080	.

O	1081	1088	Overall
O	1088	1089	,
B-total-participants	1090	1092	49
O	1093	1105	participants
O	1106	1107	(
O	1107	1111	mean
O	1112	1115	age
B-age	1116	1118	55
I-age	1119	1124	years
O	1124	1125	;
O	1126	1137	recruitment
O	1138	1142	rate
O	1143	1145	94
O	1145	1146	%
O	1146	1147	)
O	1148	1152	were
O	1153	1161	enrolled
O	1162	1165	and
O	1166	1168	96
O	1168	1169	%
O	1170	1177	adhered
O	1178	1180	to
O	1181	1184	the
O	1185	1193	exercise
O	1194	1206	prescription
O	1207	1208	(
O	1208	1217	attrition
O	1218	1222	rate
O	1223	1224	2
O	1224	1225	%
O	1225	1226	)
O	1226	1227	.

O	1228	1241	Statistically
O	1242	1253	significant
O	1254	1266	improvements
O	1267	1269	in
O	1270	1273	the
B-outcome	1274	1275	6
I-outcome	1275	1276	-
I-outcome	1276	1282	minute
I-outcome	1283	1290	walking
I-outcome	1291	1299	distance
I-outcome	1300	1304	test
O	1305	1306	(
O	1306	1307	+
O	1307	1308	7
O	1308	1309	%
O	1309	1310	,
O	1311	1312	P
O	1312	1313	<
O	1313	1314	.
O	1314	1317	001
O	1317	1318	)
O	1319	1322	and
B-outcome	1323	1332	isometric
I-outcome	1333	1343	quadriceps
I-outcome	1344	1352	strength
O	1353	1354	(
O	1354	1355	+
O	1355	1357	22
O	1357	1358	%
O	1358	1359	,
O	1360	1361	P
O	1361	1362	<
O	1362	1363	.
O	1363	1366	001
O	1366	1367	)
O	1367	1368	,
O	1369	1371	as
O	1372	1376	well
O	1377	1379	as
O	1380	1389	decreases
O	1390	1392	in
B-outcome	1393	1397	body
I-outcome	1398	1402	mass
I-outcome	1403	1408	index
O	1409	1410	(
O	1410	1411	-
O	1411	1412	2
O	1412	1413	.
O	1413	1414	5
O	1414	1415	%
O	1415	1416	,
O	1417	1418	P
O	1418	1419	=
O	1419	1420	.
O	1420	1422	03
O	1422	1423	)
O	1424	1427	and
B-outcome	1428	1431	hip
I-outcome	1432	1445	circumference
O	1446	1447	(
O	1447	1448	-
O	1448	1449	4
O	1449	1450	.
O	1450	1451	0
O	1451	1452	%
O	1452	1453	,
O	1454	1455	P
O	1455	1456	<
O	1456	1457	.
O	1457	1460	001
O	1460	1461	)
O	1462	1466	were
O	1467	1475	observed
O	1476	1478	at
O	1479	1480	6
O	1481	1487	months
O	1487	1488	.

B-outcome	1489	1496	Quality
I-outcome	1497	1499	of
I-outcome	1500	1504	life
O	1505	1513	remained
O	1514	1520	stable
O	1521	1524	and
O	1525	1526	a
O	1527	1543	nonstatistically
O	1544	1555	significant
O	1556	1564	decrease
O	1565	1566	(
O	1566	1567	-
O	1567	1569	16
O	1569	1570	%
O	1570	1571	,
O	1572	1573	P
O	1573	1574	=
O	1574	1575	.
O	1575	1577	07
O	1577	1578	)
O	1579	1581	in
O	1582	1589	fatigue
O	1590	1593	was
O	1594	1602	observed
O	1602	1603	.

O	1604	1607	The
O	1608	1612	high
O	1613	1624	recruitment
O	1625	1628	and
O	1629	1638	adherence
O	1639	1644	rates
O	1645	1652	suggest
O	1653	1656	the
O	1657	1668	willingness
O	1669	1671	of
O	1672	1680	patients
O	1681	1685	with
O	1686	1696	metastatic
O	1697	1703	breast
O	1704	1710	cancer
O	1711	1713	to
O	1714	1725	participate
O	1726	1728	in
O	1729	1730	a
O	1731	1739	physical
O	1740	1748	activity
O	1749	1756	program
O	1756	1757	.

O	1758	1761	The
O	1762	1772	beneficial
O	1773	1781	outcomes
O	1782	1791	regarding
O	1792	1800	physical
O	1801	1808	fitness
O	1809	1812	and
O	1813	1826	anthropometry
O	1827	1829	of
O	1830	1834	this
O	1835	1847	unsupervised
O	1848	1856	physical
O	1857	1865	activity
O	1866	1873	program
O	1874	1877	may
O	1878	1887	encourage
O	1888	1893	these
O	1894	1902	patients
O	1903	1905	to
O	1906	1914	maintain
O	1915	1916	a
O	1917	1927	physically
O	1928	1934	active
O	1935	1944	lifestyle
O	1944	1945	.

O	1946	1952	Future
O	1953	1963	randomized
O	1964	1974	controlled
O	1975	1981	trials
O	1982	1986	with
O	1987	1993	larger
O	1994	2000	sample
O	2001	2006	sizes
O	2007	2010	are
O	2011	2020	warranted
O	2020	2021	.

O	2022	2036	ClinicalTrials
O	2036	2037	.
O	2037	2040	gov
O	2041	2052	NCT03148886
O	2052	2053	;
O	2054	2059	https
O	2059	2060	:
O	2060	2061	/
O	2061	2062	/
O	2062	2076	clinicaltrials
O	2076	2077	.
O	2077	2080	gov
O	2080	2081	/
O	2081	2084	ct2
O	2084	2085	/
O	2085	2089	show
O	2089	2090	/
O	2090	2101	NCT03148886
O	2101	2102	.
